Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: A retrospective analysis with follow-up for 12 years

Vasavi Paidpally, Abdel K. Tahari, Stella Lam, Krishna Alluri, Shanthi Marur, Wayne Koch, Richard L. Wahl, Rathan M. Subramaniam

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

18F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of 18F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment. Methods: This was a retrospective study at a single tertiary center. The institutional review board approved this study, and the requirement to obtain informed consent was waived. The study included 134 biopsy-proven HNSCC patients with 227 followup PET/CT scans. The primary outcome measure was OS. Median follow-up was 40 mo (range, 7-145 mo). Survival is presented as Kaplan-Meier plots with Mantel-Cox log-rank test. The multivariate Cox model included clinical covariates. Results: Of the 227 PET/CT scans, 41 (18%) were positive for tumor and 186 (82%) were negative for tumor. PET/CT identified recurrence in 5% (9/194) of scans performed without prior clinical concern and ruled out tumor in 51.5% (17/33) of scans performed to evaluate clinical suspicion or uncertainty of recurrence. Themedian survival of PET-positive and -negative groups from the date of the scan was 20 and 30.5 mo, respectively (P < 0.0001). There was a significant difference in OS from the scan date between patients who had a positive PET/CT result for tumor and those who had a negative result (log-rank, P < 0.0001), with a hazard ratio of 29.74. Human papillomavirus status (P = 0.001) and PET/CT result (P = 0.04) were the only factors significantly associated with OS, adjusted for all other covariates. Conclusion: 18FFDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC. COPYRIGHT

Original languageEnglish (US)
Pages (from-to)2039-2045
Number of pages7
JournalJournal of Nuclear Medicine
Volume54
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Squamous Cell Neoplasms
Fluorodeoxyglucose F18
Head and Neck Neoplasms
Head
Survival
Uncertainty
Neoplasms
Recurrence
Time and Motion Studies
Research Ethics Committees
Informed Consent
Proportional Hazards Models
Retrospective Studies
Outcome Assessment (Health Care)
Biopsy
Therapeutics

Keywords

  • Follow-up
  • Head and neck
  • Oncology
  • PET/CT
  • Squamous cell cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC : A retrospective analysis with follow-up for 12 years. / Paidpally, Vasavi; Tahari, Abdel K.; Lam, Stella; Alluri, Krishna; Marur, Shanthi; Koch, Wayne; Wahl, Richard L.; Subramaniam, Rathan M.

In: Journal of Nuclear Medicine, Vol. 54, No. 12, 01.12.2013, p. 2039-2045.

Research output: Contribution to journalArticle

Paidpally, Vasavi ; Tahari, Abdel K. ; Lam, Stella ; Alluri, Krishna ; Marur, Shanthi ; Koch, Wayne ; Wahl, Richard L. ; Subramaniam, Rathan M. / Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC : A retrospective analysis with follow-up for 12 years. In: Journal of Nuclear Medicine. 2013 ; Vol. 54, No. 12. pp. 2039-2045.
@article{6daed14e1ec747739e0bd8f8459d5a36,
title = "Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: A retrospective analysis with follow-up for 12 years",
abstract = "18F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of 18F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment. Methods: This was a retrospective study at a single tertiary center. The institutional review board approved this study, and the requirement to obtain informed consent was waived. The study included 134 biopsy-proven HNSCC patients with 227 followup PET/CT scans. The primary outcome measure was OS. Median follow-up was 40 mo (range, 7-145 mo). Survival is presented as Kaplan-Meier plots with Mantel-Cox log-rank test. The multivariate Cox model included clinical covariates. Results: Of the 227 PET/CT scans, 41 (18{\%}) were positive for tumor and 186 (82{\%}) were negative for tumor. PET/CT identified recurrence in 5{\%} (9/194) of scans performed without prior clinical concern and ruled out tumor in 51.5{\%} (17/33) of scans performed to evaluate clinical suspicion or uncertainty of recurrence. Themedian survival of PET-positive and -negative groups from the date of the scan was 20 and 30.5 mo, respectively (P < 0.0001). There was a significant difference in OS from the scan date between patients who had a positive PET/CT result for tumor and those who had a negative result (log-rank, P < 0.0001), with a hazard ratio of 29.74. Human papillomavirus status (P = 0.001) and PET/CT result (P = 0.04) were the only factors significantly associated with OS, adjusted for all other covariates. Conclusion: 18FFDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC. COPYRIGHT",
keywords = "Follow-up, Head and neck, Oncology, PET/CT, Squamous cell cancer",
author = "Vasavi Paidpally and Tahari, {Abdel K.} and Stella Lam and Krishna Alluri and Shanthi Marur and Wayne Koch and Wahl, {Richard L.} and Subramaniam, {Rathan M.}",
year = "2013",
month = "12",
day = "1",
doi = "10.2967/jnumed.113.121285",
language = "English (US)",
volume = "54",
pages = "2039--2045",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "12",

}

TY - JOUR

T1 - Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC

T2 - A retrospective analysis with follow-up for 12 years

AU - Paidpally, Vasavi

AU - Tahari, Abdel K.

AU - Lam, Stella

AU - Alluri, Krishna

AU - Marur, Shanthi

AU - Koch, Wayne

AU - Wahl, Richard L.

AU - Subramaniam, Rathan M.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - 18F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of 18F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment. Methods: This was a retrospective study at a single tertiary center. The institutional review board approved this study, and the requirement to obtain informed consent was waived. The study included 134 biopsy-proven HNSCC patients with 227 followup PET/CT scans. The primary outcome measure was OS. Median follow-up was 40 mo (range, 7-145 mo). Survival is presented as Kaplan-Meier plots with Mantel-Cox log-rank test. The multivariate Cox model included clinical covariates. Results: Of the 227 PET/CT scans, 41 (18%) were positive for tumor and 186 (82%) were negative for tumor. PET/CT identified recurrence in 5% (9/194) of scans performed without prior clinical concern and ruled out tumor in 51.5% (17/33) of scans performed to evaluate clinical suspicion or uncertainty of recurrence. Themedian survival of PET-positive and -negative groups from the date of the scan was 20 and 30.5 mo, respectively (P < 0.0001). There was a significant difference in OS from the scan date between patients who had a positive PET/CT result for tumor and those who had a negative result (log-rank, P < 0.0001), with a hazard ratio of 29.74. Human papillomavirus status (P = 0.001) and PET/CT result (P = 0.04) were the only factors significantly associated with OS, adjusted for all other covariates. Conclusion: 18FFDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC. COPYRIGHT

AB - 18F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of 18F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment. Methods: This was a retrospective study at a single tertiary center. The institutional review board approved this study, and the requirement to obtain informed consent was waived. The study included 134 biopsy-proven HNSCC patients with 227 followup PET/CT scans. The primary outcome measure was OS. Median follow-up was 40 mo (range, 7-145 mo). Survival is presented as Kaplan-Meier plots with Mantel-Cox log-rank test. The multivariate Cox model included clinical covariates. Results: Of the 227 PET/CT scans, 41 (18%) were positive for tumor and 186 (82%) were negative for tumor. PET/CT identified recurrence in 5% (9/194) of scans performed without prior clinical concern and ruled out tumor in 51.5% (17/33) of scans performed to evaluate clinical suspicion or uncertainty of recurrence. Themedian survival of PET-positive and -negative groups from the date of the scan was 20 and 30.5 mo, respectively (P < 0.0001). There was a significant difference in OS from the scan date between patients who had a positive PET/CT result for tumor and those who had a negative result (log-rank, P < 0.0001), with a hazard ratio of 29.74. Human papillomavirus status (P = 0.001) and PET/CT result (P = 0.04) were the only factors significantly associated with OS, adjusted for all other covariates. Conclusion: 18FFDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC. COPYRIGHT

KW - Follow-up

KW - Head and neck

KW - Oncology

KW - PET/CT

KW - Squamous cell cancer

UR - http://www.scopus.com/inward/record.url?scp=84893380165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893380165&partnerID=8YFLogxK

U2 - 10.2967/jnumed.113.121285

DO - 10.2967/jnumed.113.121285

M3 - Article

C2 - 24101687

AN - SCOPUS:84893380165

VL - 54

SP - 2039

EP - 2045

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 12

ER -